KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Intangibles (2018 - 2022)

Castle Biosciences (CSTL) has disclosed Intangibles for 3 consecutive years, with $87.3 million as the latest value for Q1 2022.

  • Quarterly Intangibles changed N/A to $87.3 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $87.3 million through Mar 2022, changed N/A year-over-year, with the annual reading at $88.9 million for FY2021, N/A changed from the prior year.
  • Intangibles hit $87.3 million in Q1 2022 for Castle Biosciences, down from $88.9 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $88.9 million in Q4 2021 to a low of $4000.0 in Q4 2018.
  • Historically, Intangibles has averaged $48.2 million across 3 years, with a median of $32.8 million in 2021.